Literature DB >> 25984909

Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants.

Richard J Caselli1, Gary E Marchant, Katherine S Hunt, Bruce R Henslin, Heidi E Kosiorek, Jessica Langbaum, Jason S Robert, Amylou C Dueck.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25984909      PMCID： PMC4543388          DOI： 10.1097/WAD.0000000000000097

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


× No keyword cloud information.
  8 in total

Review 1.  Testing the right target and right drug at the right stage.

Authors:  Reisa A Sperling; Clifford R Jack; Paul S Aisen
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

2.  Subjective cognitive decline: self and informant comparisons.

Authors:  Richard J Caselli; Kewei Chen; Dona E C Locke; Wendy Lee; Auttawut Roontiva; Dan Bandy; Adam S Fleisher; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2013-04-03       Impact factor: 21.566

3.  The neuropsychology of normal aging and preclinical Alzheimer's disease.

Authors:  Richard J Caselli; Dona E C Locke; Amylou C Dueck; David S Knopman; Bryan K Woodruff; Charlene Hoffman-Snyder; Rosa Rademakers; Adam S Fleisher; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2013-03-26       Impact factor: 21.566

Review 4.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

5.  Disclosure of APOE genotype for risk of Alzheimer's disease.

Authors:  Robert C Green; J Scott Roberts; L Adrienne Cupples; Norman R Relkin; Peter J Whitehouse; Tamsen Brown; Susan LaRusse Eckert; Melissa Butson; A Dessa Sadovnick; Kimberly A Quaid; Clara Chen; Robert Cook-Deegan; Lindsay A Farrer
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

6.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

7.  Public perceptions of presymptomatic testing for Alzheimer disease.

Authors:  Richard J Caselli; Jessica Langbaum; Gary E Marchant; Rachel A Lindor; Katherine S Hunt; Bruce R Henslin; Amylou C Dueck; Jason S Robert
Journal:  Mayo Clin Proc       Date:  2014-08-26       Impact factor: 7.616

8.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Authors:  Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong
Journal:  Alzheimers Res Ther       Date:  2011-01-06       Impact factor: 6.982
  8 in total
  4 in total

1.  Safety of disclosing amyloid status in cognitively normal older adults.

Authors:  Jeffrey M Burns; David K Johnson; Edward P Liebmann; Rebecca J Bothwell; Jill K Morris; Eric D Vidoni
Journal:  Alzheimers Dement       Date:  2017-03-03       Impact factor: 21.566

2.  Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.

Authors:  Victoria S Marshe; Ilona Gorbovskaya; Sarah Kanji; Maxine Kish; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-10-31       Impact factor: 3.575

Review 3.  Study partners should be required in preclinical Alzheimer's disease trials.

Authors:  Joshua D Grill; Jason Karlawish
Journal:  Alzheimers Res Ther       Date:  2017-12-06       Impact factor: 6.982

4.  Recruiting to preclinical Alzheimer's disease clinical trials through registries.

Authors:  Joshua D Grill
Journal:  Alzheimers Dement (N Y)       Date:  2017-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.